Dexcom Inc header image

Dexcom Inc

DXCM

Equity

ISIN null / Valor 2107726

NASDAQ (2025-11-21)
USD 60.23+3.10%

Dexcom Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Dexcom Inc is a San Diego-based company that specializes in continuous glucose monitoring (CGM) systems for diabetes management. As a leader in diabetes care technology, Dexcom focuses on empowering users, caregivers, and healthcare providers by providing innovative solutions that simplify and improve diabetes management globally. Dexcom's products, including Dexcom G6, Dexcom Share, and Dexcom CLARITY, have been recognized for their accuracy, utilization, and effectiveness in monitoring glucose levels. With a commitment to listening to the needs of their customers, Dexcom continues to drive advancements in CGM technology to help individuals take control of their diabetes.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (24.10.2025):

Dexcom Inc reported robust financial performance for the second quarter of 2025, achieving a 15% year-over-year revenue growth and significant improvements in operating income.

Revenue Growth

Dexcom Inc's revenue increased by 15% year-over-year to $1.157 billion in the second quarter of 2025. U.S. revenue grew by 15%, while international revenue saw a 16% increase on a reported basis.

Operating Income

The company's GAAP operating income rose to $212.6 million, representing 18.4% of revenue, marking a 270 basis point improvement compared to the second quarter of 2024. Non-GAAP operating income was $221.8 million, or 19.2% of revenue.

Net Income

GAAP net income for the second quarter of 2025 was $179.8 million, or $0.45 per diluted share, up from $143.5 million, or $0.35 per diluted share, in the same quarter last year.

Cash and Liquidity

As of June 30, 2025, Dexcom held $2.93 billion in cash, cash equivalents, and marketable securities, providing significant financial flexibility for future growth initiatives.

Annual Guidance

Dexcom raised its fiscal year 2025 revenue guidance to $4.600 - $4.625 billion, representing 14-15% growth, and reiterated its guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin.

Summarized from source with an LLMView Source

Key figures

-19.1%1Y
-46.5%3Y
-23.7%5Y

Performance

45.6%1Y
50.9%3Y
49.2%5Y

Volatility

Market cap

23491 M

Market cap (USD)

Daily traded volume (Shares)

5,453,686

Daily traded volume (Shares)

1 day high/low

79.28 / 77.68

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Edwards Lifesciences Corp
Edwards Lifesciences Corp Edwards Lifesciences Corp Valor: 1065343
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.24%USD 85.13
Dyne Therapeutics Inc
Dyne Therapeutics Inc Dyne Therapeutics Inc Valor: 56806425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.27%USD 21.18
Boiron SA
Boiron SA Boiron SA Valor: 487646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.95%EUR 26.60
Bright Horizons Family Solutions
Bright Horizons Family Solutions Bright Horizons Family Solutions Valor: 19920287
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.62%USD 101.12
Dr Reddy'S Laboratories Ltd
Dr Reddy'S Laboratories Ltd Dr Reddy'S Laboratories Ltd Valor: 1221723
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.07%USD 13.91
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA SCHOTT Pharma AG & Co. KGaA Valor: 128964250
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.66%EUR 18.44
Coloplast A/S
Coloplast A/S Coloplast A/S Valor: 20259063
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.55%DKK 580.20
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.21%USD 5.03
Essity AB
Essity AB Essity AB Valor: 36851944
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.79%SEK 260.90
Lifco Ab
Lifco Ab Lifco Ab Valor: 111355378
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.18%SEK 342.20